Rapacuronium Uses, Dosage, Side Effects and more
Rapacuronium was withdrawn in 2001 in many countries due to risk of fatal bronchospasm.
Rapacuronium is a rapidly acting, non-depolarizing neuromuscular blocker.
| Trade Name | Rapacuronium |
| Availability | Discontinued |
| Generic | Rapacuronium |
| Type | |
| Formula | C37H61N2O4 |
| Weight | Average: 597.904 Monoisotopic: 597.462584872 |
| Protein binding | Variable. Plasma protein binding of rapacuronium was studied in vitro for human plasma by equilibrium dialysis. The protein binding was variable and ranged between 50% and 88%, which was at least partly due to hydrolysis of rapacuronium bromide to its 3-hydroxy metabolite. The specific plasma protein to which rapacuronium binds is unknown. Plasma protein binding of the 3-hydroxy metabolite was not determined. |
| Groups | Approved, Withdrawn |
| Therapeutic Class | |
| Manufacturer | |
| Available Country | |
| Last Updated: | January 7, 2025 at 1:49 am |
Uses
Rapacuronium is a nondepolarizing neuromuscular blocking agent used as an adjunct to general anesthesia to facilitate tracheal intubation, and to provide skeletal muscle relaxation during surgical procedures.
Used in anaesthesia, to aid and enable endotracheal intubation.
Rapacuronium Disease Interaction
Major: burns, histamine release, myasthenia gravis, paresis, pulmonary impair
Half Life
141 minutes (mean)
